Skip to main content
Livermore
Livermore
ZHEN

Mizuho Markets Cayman LP

SEC CIK
0001803149
Latest filing
Jul 24, 2026

The latest 13F from Mizuho Markets Cayman LP covers Q2 2026 (filed Jul 24, 2026): 89 long positions worth $2.67B. The top 10 holdings make up 74.2% of the portfolio, and the largest is Marvell Technology, Inc. (MRVL) at 21.2%. Livermore has 24 filings on Form 13F from this institution, going back to Q1 2021.

What changed in Q2 2026

Share counts compared with Q1 2026: how many positions were new, added to, reduced or sold out, and the biggest buys and sells. Dollar amounts are estimated at the quarter-end prices implied by the filing.

Full comparison
New
47
Est. +$1.23B
Added
21
Est. +$403.6M
Reduced
20
Est. −$83.9M
Sold out
36
Est. −$1.02B

Top 5 holdings

Share of this quarter's portfolio value

  1. MRVLMarvell Technology, Inc.
    21.2%$566.3MHistory
  2. DELLDell Technologies Inc.
    11.1%$296.3MHistory
  3. iShares Core S&P 500 ETF464287200
    7.7%$206.5M
  4. MSFTMicrosoft Corp
    7.5%$199.5MHistory
  5. METAMeta Platforms, Inc.
    7.4%$196.5MHistory

Share of portfolio

Top 5 holdings and the other 84 positions, by share of portfolio value

  1. MRVL21.2%
  2. DELL11.1%
  3. iShares Core S&P 500 ETF7.7%
  4. MSFT7.5%
  5. META7.4%
  6. Other 84 positions45.0%

Biggest buys

New and added positions, by estimated amount bought

  1. MRVLMarvell Technology, Inc.
    +$566.3MNewHistory
  2. PANWPalo Alto Networks Inc
    +$193.6MAddedHistory
  3. iShares Core S&P 500 ETF464287200
    +$163.0MAdded
  4. ABTAbbott Laboratories
    +$144.1MNewHistory
  5. HALOHalozyme Therapeutics, Inc.
    +$65.3MNewHistory

Largest weight increases

New and added positions, by percentage points of the portfolio gained

  1. MRVLMarvell Technology, Inc.
    +21.25 pp0.0% → 21.2%History
  2. PANWPalo Alto Networks Inc
    +7.27 pp<0.1% → 7.3%History
  3. iShares Core S&P 500 ETF464287200
    +5.71 pp2.0% → 7.7%
  4. ABTAbbott Laboratories
    +5.41 pp0.0% → 5.4%History
  5. HALOHalozyme Therapeutics, Inc.
    +2.45 pp0.0% → 2.5%History

Biggest sells

Reduced and sold-out positions, by estimated amount sold

  1. GEHCGE HealthCare Technologies Inc.
    −$218.4MSold outHistory
  2. AMGNAmgen Inc
    −$172.0MSold outHistory
  3. ADIAnalog Devices Inc
    −$150.3MSold outHistory
  4. XOMExxonMobil Holdings Corp
    −$149.3MSold outHistory
  5. MCHPMicrochip Technology Inc
    −$100.2MSold outHistory

Largest weight decreases

Reduced and sold-out positions, by percentage points of the portfolio lost

  1. GEHCGE HealthCare Technologies Inc.
    −11.75 pp11.7% → 0.0%History
  2. AMGNAmgen Inc
    −9.25 pp9.3% → 0.0%History
  3. ADIAnalog Devices Inc
    −8.08 pp8.1% → 0.0%History
  4. XOMExxonMobil Holdings Corp
    −8.03 pp8.0% → 0.0%History
  5. MCHPMicrochip Technology Inc
    −5.39 pp5.4% → 0.0%History

Metrics

13F metrics for Q2 2026, computed only from the numbers in the filings. Definitions below.

Portfolio value
$2.67B
+$805.9M (+43.3%) vs. prior quarter
Positions
89
+11 vs. prior quarter
Top 10 concentration
74.2%
Top 10 as share of value
Turnover
49.0%
Q2 2026, one quarter
Average holding period
2.2 quarters
Weighted by value

How these are calculated

  • Portfolio value: the market value of all long positions in the 13F, as reported at quarter end, excluding options.
  • Top 10 concentration: the combined value of the 10 largest positions as a share of portfolio value.
  • Turnover: the smaller of this quarter's estimated purchases and estimated sales, divided by the average of this and last quarter's portfolio value. Estimates multiply the change in shares by the quarter-end price implied by the filing (market value divided by shares); new positions use this quarter's value and sold-out positions last quarter's. Only positions reported in shares count, and it is not calculated when the previous quarter was not filed.
  • Average holding period: how many consecutive quarters each current position has been held (including this one; a quarter without the position or without a filing starts the count over), weighted by this quarter's value. Counting starts with the first 13F in Livermore (Q1 2021), so positions held before then are understated.

13F filings by quarter

22 quarters, going back to Q1 2021. Bars show each quarter's 13F portfolio value; quarters without a filing are left blank.

Peak $2.67B (Q2 2026)

Q1 2021: $708.3MQ2 2021: $543.5MQ3 2021: $1.10BQ4 2021: $985.9MQ1 2022: $937.4MQ2 2022: $585.7MQ3 2022: $699.1MQ4 2022: $734.1MQ1 2023: $2.33BQ2 2023: $516.7MQ3 2023: $225.8MQ4 2023: $114.2MQ1 2024: $162.9MQ2 2024: $21.6MQ3 2024: $22.6MQ4 2024: $40.3MQ1 2025: $24.0MQ2 2025: $1.39BQ3 2025: $1.17BQ4 2025: $1.98BQ1 2026: $1.86BQ2 2026: $2.67B
Q1 2021Q2 2026
13F filings of Mizuho Markets Cayman LP by quarter
QuarterFiledPositionsValueTop 3 holdingsChangesFiling
Q2 2026Jul 24, 202689$2.67BMRVLDELLiShares Core S&P 500 ETFvs. Q1 2026SEC
Q1 2026May 13, 202678$1.86BGEHCMETAMSFTvs. Q4 2025SEC
Q4 2025Feb 6, 202693$1.98BMSFTMETAXOMvs. Q3 2025SEC
Q3 2025Nov 19, 2025Amended86$1.17BINTCXOMAMGNvs. Q2 2025SEC
Q2 2025Aug 1, 202577$1.39BFCXXOMINTCvs. Q1 2025SEC
Q1 2025May 12, 202521$24.0MAMDARMNVDAvs. Q4 2024SEC
Q4 2024Feb 11, 202519$40.3MTSLAMSFTAAPLvs. Q3 2024SEC
Q3 2024Nov 6, 202419$22.6MGOOGLARMAAPLvs. Q2 2024SEC
Q2 2024Jul 31, 202420$21.6MGOOGLXYZINTCvs. Q1 2024SEC
Q1 2024May 10, 202436$162.9MAMDMETAAMATvs. Q4 2023SEC
Q4 2023Feb 8, 202426$114.2MAMDAMATMETAvs. Q3 2023SEC
Q3 2023Nov 9, 202334$225.8MMETAAMZNAMATvs. Q2 2023SEC
Q2 2023Aug 14, 2023Amended33$516.7MMETAAMDAMZNvs. Q1 2023SEC
Q1 2023May 3, 202372$2.33BFDXMCHPFISvs. Q4 2022SEC
Q4 2022Feb 3, 202345$734.1MNVDAAMZNMETAvs. Q3 2022SEC
Q3 2022Oct 24, 202250$699.1MNVDABABAMETAvs. Q2 2022SEC
Q2 2022Jul 28, 202251$585.7MBABANVDAAMZNvs. Q1 2022SEC
Q1 2022Apr 27, 202256$937.4MNVDABABASPYvs. Q4 2021SEC
Q4 2021Jan 28, 202255$985.9MBABASPYNVDAvs. Q3 2021SEC
Q3 2021Oct 28, 202154$1.10BBABASPYNVDAvs. Q2 2021SEC
Q2 2021Jul 28, 202149$543.5MSPYXYZAAPLvs. Q1 2021SEC
Q1 2021Apr 28, 202155$708.3MBABASPYAAPL–SEC